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1. Introduction 
Type 1 diabetes is a complex autoimmune disease in which genetic and environmental 
factors add up to induce an autoimmune destruction of the insulin-producing pancreatic  
cells. Although type 1 diabetes is popularly associated to an onset in infancy or adolescence, 
it can begin at any age. The reasons behind this temporal difference in the onset of the 
disease are probably a mixture of genetic and environmental factors, just as the induction of 
the disease itself. Despite the great progress that the study of the genetics of type 1 diabetes 
has experienced in the last years, the genetic factors that could modify the age at diagnosis 
of type 1 diabetes have not been analyzed so deeply. This knowledge would be interesting 
to discover new routes to delay the disease onset and preserve the  cell mass as long as 
possible. In this chapter, we will review the characteristics of adult-onset type 1 diabetes 
patients and afterwards we will focus on the studies in type 1 diabetes genetics and the 
reported associations of genetics and age at onset of the disease. Finally, we will present an 
analysis of ten genetic associations in a group of Spanish patients with early and late onset 
of type 1 diabetes.  
2. Diagnostic criteria for diabetes and further classification of the disease 
Type 1 diabetes is the most prevalent chronic disease in childhood and it is also the most 
frequent form of diabetes in subjects diagnosed before age 19 (Duncan, 2006). Adults can 
also suffer from type 1 diabetes, given that the prevalence rate does not vary greatly with 
age, but the diagnosis of the disease in adult age is complicated by the higher prevalence of 
type 2 diabetes, which is the most frequent form of diabetes in adulthood (American 
Diabetes Association [ADA], 2010). Classical diabetes classifications used to categorize 
patients by their age at diagnosis or insulin requirement. Thus, type 1 diabetes was termed 
juvenile diabetes or insulin-dependent diabetes mellitus (IDDM) and type 2 diabetes could 
be diabetes of the adult or non-insulin dependent diabetes mellitus (NIDDM). However, 
type 2 diabetes can begin as an insulin-dependent condition or at an early age, type 1 
diabetes can begin at any age, and a certain form of adult onset autoimmune diabetes 
termed latent autoimmune diabetes of the adult (LADA) is non-insulin-dependent by 
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definition at the time of diagnosis, nevertheless it is an autoimmune form of diabetes. 
Therefore, cataloging the different forms of diabetes is not so simple and classifications 
based in age at diagnosis or insulin requirement are no longer employed. Hence, we will 
review the diagnostic criteria for diabetes and define what can be considered adult-onset 
type 1 diabetes.  
According to the most recent classification of the American Diabetes Association (ADA, 
2010), the diagnostic criteria for diabetes are 1) levels of glycosilated haemoglobin over 6.5%, 
2) fasting plasma glucose levels over 126 mg/dl, defining fasting state as no caloric intake 
for at least eight hours, 3) plasma glucose over 200 mg/dl at two hours during an oral 
glucose tolerance test (OGTT) or 4) random plasma glucose over 200 mg/dl in a patient with 
classic symptoms of hyperglycemia (poliuria, polidypsia or glucosuria). Patients with type 
1, type 2 diabetes or LADA must feet these criteria. Then, further classification of the patient 
should be considered.  
2.1 Type 1 diabetes 
Type 1 diabetes accounts for 5-10% of the total cases of diabetes and it is the 90% of the cases 
of diabetes diagnosed in children (ADA, 2010). The disease is an autoimmune condition 
characterized by the destruction of the pancreatic cells by autoreactive T lymphocytes. 
Hyperglicemia manifests when 60-90% of the  cell mass has been lost. As a result of the 
autoimmune insult, antibodies against pancreatic islets are synthesized and can be 
detectable in serum (see table 1). These antibodies precede in several years the clinical 
symptoms. They are not pathogenic (Wong et al, 2010), but its detection helps in the 
classification of the patient as type 1 diabetes, especially when the disease is diagnosed in 
adulthood. Antibodies against pancreatic antigens are positive at diagnosis in 90% of type 1 
diabetes patients. Obesity is quite uncommon in these patients, but not incompatible with 
the disease. Patients are frequently insulin-dependent since diagnosis and insulin-
replacement therapy is ultimately necessary for survival. Also, C-peptide levels (a measure 
of  cell activity) are usually low or undetectable. When untreated, type 1 diabetes leads to 
diabetic ketoacidosis, a life-threatening condition derived from the use of fat deposits (ADA, 
2010).  
Adult-onset type 1 diabetes patients tend to have a softer disease onset, with a lower 
frequency of diabetic ketoacidosis and a slower loss of insulin secretion capacity 
(Hosszufalusi et al, 2003; Leslie et al, 2006). These characteristics lead to think that a slower 
autoimmune reaction is taking place in the patient with adult onset.  
 
 Autoantibody Antigen expression 
IAA Anti-insulin antibodies Pancreas 
GADA Anti-glutamate decarboxilase antibodies Pancreas/nervous system 
IA2-A Anti-insulinoma associated 2 antibodies Pancreas 
ICA Anti-islet cell antibodies (several antigens) Pancreas 
SCL38A Antibodies against the zinc channel ZnT8 Pancreas 
Table 1. Autoantibodies against pancreatic antigens in type 1 diabetes.  
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2.2 Type 2 diabetes 
Type 2 diabetes includes 90-95% of the total cases of diabetes and accounts for 80-85% of 
the cases diagnosed in adulthood (ADA, 2010). The disease is a result of a combination of 
peripheral insulin resistance and relative insulin deficiency that develops into 
hyperglycemia. The hyperglycemia in type 2 diabetes appears gradually, usually with 
absence of the classic symptoms (polyuria, polydipsia) and can go undetected for long 
time before diagnosis. The etiologic factors of type 2 diabetes are unknown and probably 
this trait, more than type 1 diabetes, is composed of several different diseases with the 
common clinical manifestation of hyperglycemia. However, there is no proof of an 
implication of an autoimmune response, and thus autoantibodies against pancreatic 
antigens are always negative (ADA, 2010). Patients are usually obese and non-insulin 
dependent, although insulin can become a necessary therapy for a good control of 
hyperglycemia in some cases. However, insulin treatment in type 2 diabetes is not 
required for survival. C-peptide levels can be lower than in healthy controls, reflecting the 
relative insulin deficiency, but they are higher than in type 1 diabetes patients and 
decrease more gradually with time (Hosszufalusi et al, 2003). Diabetic ketoacidosis is 
quite rare and tends to develop due to underlying conditions, such as an infection (ADA, 
2010).  
2.3 Latent autoimmune diabetes of the adult (LADA) 
Early after the discovery of antibodies against pancreatic antigens in the serum of type 1 
diabetic subjects, it was noticed by clinicians that 10% of patients first diagnosed with type 2 
diabetes tested positive for type 1 diabetes antibodies (mainly GADA and ICA) (Palmer et 
al, 2005). Those patients slowly but relentlessly progressed to insulin-dependency and 
showed signs of pancreatic islet dysfunction such as a progressive decrease of C-peptide 
levels. These characteristics defined a new category in the diabetes spectra called the latent 
autoimmune diabetes of the adult, and abbreviated LADA. Diagnostic criteria for these 
patients are age at diagnosis over 30 years, presence of antibodies against pancreatic islets, 
with a higher frequency of single positivity and GADA or ICA antibodies than type 1 
diabetes patients, and no requirement of insulin for at least six months since diagnosis 
(Palmer et al, 2005; Leslie et al, 2006). There seems to exist a similar but milder genetic 
background to that of type 1 diabetic patients (Hosszufalusi et al, 2003; Palmer et al, 2005), 
and some researchers think of LADA as a slower and less aggressive form of type 1 
diabetes, to the point that this condition is usually termed type 1.5 diabetes. Debate exists 
over LADA being an entity of its own or just a less aggressive form of type 1 diabetes at an 
older age (Hosszufalusi et al, 2003; Palmer et al, 2005; Leslie et al, 2006; Steck & Eisenbarth, 
2008). Anyway, this group of patients poses a very interesting subset for testing  cell 
preserving therapies in an autoimmune form of diabetes due to its slow progression to 
insulin-dependency.   
2.4 The diagnosis of an adult-onset diabetic patient 
When recruiting patients for genetic studies, a careful evaluation of adult-onset patients 
must be carried out to avoid misclassification. In most cases, the three more common forms 
of diabetes in adults can be distinguished with a test for antibodies against pancreatic 
antigens at diagnosis and the requirement for insulin therapy (see table 2).  
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Adult-onset type 
1 diabetes 
Type 2 diabetes LADA 
Insulin requirement 
Ultimately 
needed for 
survival 
Useful for improved 
glycemic control in 
some cases 
 
Not for the first 6 
months after diagnosis. 
Patients eventually 
evolve to insulin-
dependency 
 
Corporal phenotype Usually lean Usually obese Variable 
Antibodies 2 or more positive Negative 
At least 1 positive 
High frequency of 
GADA+ and/or ICA+ 
C-peptide levels Low or absent 
Normal or slightly 
decreased 
Low 
Diabetic ketoacidosis Present Rare Rare 
T-cell response against 
pancreatic islet antigens 
Positive Negative Positive 
Type 1 diabetes HLA 
susceptibility 
Present Absent Present 
% of total adult diabetes 5-10% 80-85% 5-10% 
Table 2. Summary of the characteristics of the three more common forms of diabetes in 
adulthood: adult-onset type 1 diabetes, type 2 diabetes and LADA (Leslie et al, 2006; ADA, 
2010). 
The subgroup of adult-onset type 1 diabetic patients is relatively easy to separate from the 
other two clinical manifestations of diabetes in adulthood: patients should be insulin-
dependent since diagnosis, positive for at least two type 1 diabetes autoantibodies and 
usually of lean body type. However, many genetic studies in the last years have excluded 
the adult subset of type 1 diabetic patients as a precaution to avoid contamination with type 
2 diabetic patients. This conservative measure has excluded a group of patients that could 
give us important information about the genetics of the disease: the existence of genes that 
modify the progression of the disease, together with unknown environmental factors, which 
would be the causatives of the fast immune  cell destruction in a child and the slower 
destruction in an adult patient.  
From now on, we will focus on the genetics of type 1 diabetes and the study of the influence 
of genetics in age at disease onset. 
3. Genetic studies in type 1 diabetes 
The existence of a genetic basis that influences the development of type 1 diabetes is 
known since the first studies associated alleles and haplotypes in the Human Leukocyte 
Antigen (HLA) complex with type 1 diabetes risk in the late 70s (Nerup et al, 1974). 
Familial studies have been able to quantify the genetic basis of the disease in a range 
between 30-70% of the total contributing factors, being the remainder due to 
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environmental factors (Redondo et al, 2001a; Pociot et al, 2010). Half of this genetic 
contribution is due to alleles and haplotypic combinations in the HLA region (Erlich et al, 
2008), which is the strongest genetic modifier of type 1 diabetes risk. The rest of the 
genetic load is composed of genes with smaller effects, some of which have been unveiled 
in the last thirty years through different approaches developed as the technology for DNA 
study evolved. These studies ranged from the association studies of candidate genes to 
the complex hypothesis-free genome-wide association studies. In this section, we will 
briefly review the methodology employed in these studies and its importance in the 
unraveling of the type 1 diabetes genetic component.   
3.1 Association studies of candidate genes 
The association studies are suited for the detection of variants with moderate or low 
effects on the disease, as long as the studied variants are relatively frequent in the 
population of study (minor allele frequency over 5%) (Pociot et al, 2010; Steck & Rewers, 
2011). Association can be measured in a case-control design (study of the differences 
between a set of unrelated patients and healthy controls) or a family design (analysis of 
deviations in the theoretical 50% transmission of the variant from healthy parents to 
patients). Previous to the massive knowledge that the Human Genome Project provided 
to genetic studies in humans, association studies had to focus on the selection of 
candidate genes, which limited these studies to genes with known function and biased the 
selection by what was known (or believed) about the pathogenesis of the disease at the 
moment. Nevertheless, this approach discovered the five classical regions associated with 
type 1 diabetes and detailed in table 3.   
 
First reported Gene Function 
1970-1980 
(Nerup et al, 1974) 
HLA class II Antigen presentation in antigen-presenting cells. 
1984 
(Bell et al, 1984) 
INS 
Expression levels in the thymus regulate the 
presence of insulin-reactive T cells. 
1996 
(Nistico et al, 1996) 
CTLA4 
Modulator of inactivation of the immune 
response. Constitutively expressed in regulatory 
T cells, a lymphocyte subset specialized in the 
suppression of autoimmunity. 
2004 
(Bottini et al, 2004) 
PTPN22 
Suppressor of signals through the TCR. 
Susceptibility variant is believed to favor the 
survival of auto-reactive T cells in the thymus. 
2005 
(Vella et al, 2005) 
IL2RA 
Alpha subunit of the high affinity IL2 receptor. 
Constitutively expressed in regulatory T cells, it 
is essential for the maintenance of this cell subset. 
Table 3. Classical type 1 diabetes associated genes discovered through association studies of 
candidate genes. TCR: T cell receptor. 
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3.2 The genome wide association studies 
The first genome-wide association study was published in 2007 (The Wellcome Trust Case-
Control Consortium [WTCCC], 2007). Samples from seven diseases (among them type 1 and 
type 2 diabetes) were collected, recruiting 2000 cases of each disease and a common subset 
of 3000 healthy controls. This single study described four new regions strongly associated 
with type 1 diabetes, almost the same number of regions that the previous association 
studies had taken three decades to discover.    
Genome-wide association studies were possible thanks to the great development in the 
knowledge of human genetics and in the techniques to study DNA, derived from initiatives 
such as the Human Genome Project. The design of a genome-wide study is based on the 
analysis of over 500.000 single nucleotide polymorphisms (SNPs) throughout the genome in 
each subject recruited. The study design is usually a case-control approach, but both case-
control and family studies are commonly used to replicate the stronger associations in the 
recent genome-wide studies (Hakonarson et al, 2007; Barrett et al, 2009). Since their object of 
analysis is the whole genome, these kind of studies are hypothesis-free and are able to detect 
associations in regions and genes that a candidate gene study would have never considered, 
such as regions with genes of unknown function and genes in routes not classically 
considered to take part in the pathogenesis of the disease. Thus, from the four regions 
associated with type 1 diabetes and described in the WTCCC study (WTCCC, 2007), one 
(16p13) covered a gene of unknown function, and two (12q13 and 12q24) pointed to regions 
with several candidate genes.  
Despite the advantage that poses the hypothesis-free design, the genome-wide association 
studies have a great disadvantage in return: the high number of polymorphisms studied 
implies an elevated number of statistical comparisons and an increased probability of 
obtaining false-positive associations. Therefore, these studies are subject to a strong statistical 
correction (WTCCC, 2007), and, depending on the number of markers analyzed, p values 
should be as low as 10-7 to be considered statistically significant (Todd et al, 2007). Moreover, 
the results obtained (especially those that are borderline significant) should be replicated in 
independent populations to assure that the result is not a false positive and it is not influenced 
by population variability (McCarthy et al, 2008). At this stage is where follow-up studies take 
place. Follow-up studies select associations from genome-wide studies for replication 
purposes, being the more interesting those that are borderline significant.  
Genome-wide association studies and their follow-up have been successful in uncovering 
associations of high to moderate effect (odds ratio over 1.15) in variants with a minor allele 
frequency over 5%. Now, the remainder of the genetic component in type 1 diabetes is 
proposed to reside in rare variants with high effect and common variants with low effect on 
the disease (Pociot et al, 2010). Due to the stringent statistical correction required, genome-
wide studies are not suitable for detecting these associations and new approaches will be 
necessary. Despite their limitations, in just five years genome-wide studies have revealed 
ten times more genetic regions than the older approaches did in thirty years, providing fifty 
genetic regions associated with type 1 diabetes. A brief summary of these regions can be 
consulted in table 4.  
3.3 The problem with age at diagnosis 
Although type 1 diabetes has a similar prevalence in all ages, the restriction to pediatric 
patients has been a popular criterion for recruitment of patients in studies on the genetics of 
the disease, as it is shown in table 5. Its purpose is to avoid the inclusion of misdiagnosed  
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Chromosome Candidate gene OR Reference study 
Published age-at-
onset analysis 
1p13.2 PTPN22 2.05 (Smyth et al. 2008) Yes 
1q31.2 RGS1 0.89 (Smyth et al. 2008)  
1q32.1 IL20-IL10-IL19 0.84 (Barrett et al. 2009)  
2q11.2 Several -- (Barrett et al. 2009)  
2q24.2 IFIH1 0.86 (Smyth et al. 2008)  
2q32.2 STAT4 1.10 (Fung et al. 2009) Yes 
2q33.2 CTLA4 0.82 (Smyth et al. 2008)  
3p21.31 CCR5 0.85 (Smyth et al. 2008)  
4p15.2 AC111003.1 1.09 (Barrett et al. 2009)  
4q27 IL2-IL21 1.13 (Barrett et al. 2009)  
6p21 HLA 0.02-49.2 
(Ounissi-Benkalha 
and Polychronakos 
2008) 
Yes 
6q15 BACH2 1.13 (Cooper et al. 2008)  
6q22.32 CENPW 1.17 (Barrett et al. 2009)  
6q23.3 TNFAIP3 0.90 (Fung et al. 2009)  
6q25.3 TAGAP 0.92 (Smyth et al. 2008)  
7p15.2 Several 0.88 (Barrett et al. 2009)  
7p12.1 COBL 0.77 (Barrett et al. 2009)  
9p24.2 GLIS3 0.88 (Barrett et al. 2009)  
10p15.1 IL2RA 0.62 (Smyth et al. 2008) Yes 
10p15.1 PRKCQ 0.69 (Lowe et al. 2007)  
10q22.3 ZMIZ1 -- (Barrett et al. 2009)  
10q23.31 RNLS 0.75 (Barrett et al. 2009)  
11p15.5 INS 0.42 (Smyth et al. 2008) Yes 
12p13.31 CLEC2D-CD69 1.09 (Barrett et al. 2009)  
12q13.3 CYP27B1 1.22 (Bailey et al. 2007)  
12q13.2 ERBB3 1.31 (Barrett et al. 2009) Yes 
12q24.12 SH2B3 1.28 (Smyth et al. 2008) Yes 
13.32.3 GRP183 1.15 (Heinig et al. 2010)  
14q24.1 Several 0.86 (Barrett et al. 2009)  
14q32.2 Several 1.09 (Barrett et al. 2009)  
14q32.2 Several 0.90 (Wallace et al. 2009)  
15q14 RASGRP1 1.21 (Qu et al. 2009)  
15q25.1 CTSH 0.86 (Smyth et al. 2008)  
16p13.13 CLEC16A 0.81 (Smyth et al. 2008) Yes 
16p11.2 IL27 0.86 (Barrett et al. 2009)  
16q23.1 Several 1.28 (Barrett et al. 2009)  
17q12 Several 0.87 (Barrett et al. 2009)  
17q21.2 SMARCE1 0.95 (Barrett et al. 2009)  
Table 4. Summary of the 50 chromosomal regions currently associated with type 1 diabetes 
(continues in next page). The odds ratio in the table has been extracted from the reference 
study. Data come from the on-line database www.t1dbase.org, belonging to the Type 1 
Diabetes Genetics Consortium (T1DGC). The reference study does not correspond with the 
published age-at-onset study. Genes CLEC16A and SH2B3 were analyzed in Todd et al 
(2007) and where not associated with age at onset. The rest of the age-at-onset associations 
are reviewed in section 4.  
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Chromosome Candidate gene OR Reference study 
Published age-at-
onset analysis 
18p11.21 PTPN2 1.28 (Smyth et al. 2008) Yes 
18q22.2 CD226 1.16 (Smyth et al. 2008)  
19p13.2 TYK2 0.86 (Wallace et al. 2009)  
19q13.32 Several 0.86 (Barrett et al. 2009)  
19q13.4 FUT2 -- (Barrett et al. 2009)  
20p13 Several 0.90 (Barrett et al. 2009)  
21q22.3 UBASH3A 1.13 (Smyth et al. 2008)  
22q12.2 Several 1.10 (Barrett et al. 2009)  
22q12.3 IL2RB -- (Barrett et al. 2009)  
22q13.1 C1QTNF6 1.11 (Cooper et al. 2008)  
Xp22.2 TLR8 0.84 (Barrett et al. 2009)  
Xq28 Several 1.16 (Barrett et al. 2009)  
Table 4 (continuation). Summary of the 50 chromosome regions currently associated with 
type 1 diabetes.  
patients (type 2 diabetics or LADA patients) within adult-onset diabetic patients. However, 
enough criteria exist to discriminate type 1 diabetic patients from the remainder of diabetic 
adults, and the exclusion of adult type 1 diabetes patients limits the knowledge of the 
genetics of the disease only to its early onset. Adult-onset patients show signs of a slower 
immune reaction to  cells. The factors that cause a rapid destruction of  cells in a child but 
a slower degeneration in an adult-onset patient are unknown, nevertheless they are 
probably a mixture of genetic and environmental factors. Some hypotheses may explain the 
different speed in clinical manifestations: the genetic load of adult-onset diabetes could be 
composed of a lower number of associated genes than in the early-onset patients, or could 
be the same genes but with less effect in the adult disease, or maybe the adult-onset 
population has genes associated that are exclusive of adult-onset. Besides, the simple 
replication in adult-onset patients of associations found in pediatric type 1 diabetes is 
interesting to prove that, from a genetic perspective, adult-onset patients are as much type 1 
diabetes as the pediatric-onset ones.   
Four genome-wide studies and a series of follow-up have been published in type 1 diabetes 
in the last five years (table 5). Two included systematically some adult-onset patients in their 
populations; however most of these studies lacked an analysis of the influence of genetics in 
the age of diagnosis. The characteristics of the four genome-wide and some selected follow-
up and major genetic studies, and the populations included in them, can be consulted in 
table 5.  
The two populations that recruit late-onset patients deserve a more detailed commentary. 
The GoKinD (Genetics of kidneys in diabetes) population, included in Cooper et al in 2008, 
belongs to a United States project that aims at studying the genetics of kidney diseases in 
type 1 diabetes. Selection criteria for type 1 diabetes were age at diagnosis before 31 years, 
insulin therapy needed within the first year of diagnosis and not interrupted for any reason 
ever since. Patients had a minimum disease duration of 10 years. Analysis of the influence of 
genetics in age at diagnosis was not carried out in this genome-wide study. 
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Study 
Year of 
publication 
Population 
Age limit for 
selection of 
participants 
Study of 
genetics 
and age at 
diagnosis 
(1) WTCCC 2007 2000 cases, British 
Diagnosis before 17 
years 
No 
(2) Todd et al 
2007 
Follow-up from 
WTCCC 
4000 cases and 2997 
British families 
Diagnosis before 17 
years 
Yes 
(3) Hakonarson et al 2007 
563 cases and 1422 
families from Britain, 
the US and Australia 
Most diagnosed 
before 18 years 
No 
(4) Cooper et al 2008 
GoKinD population 
1785 US cases 
Diagnosis before 31 
years 
No 
(5) Smyth et al 
2008 
Major genetic 
study 
8064 cases and 3064 
families from US, 
Finland, Ireland, 
Norway and 
Romania 
Diagnosis before 17 
years 
No 
(6) Barrett et al 2009 
T1DGC population 
3983 cases and 2319 
families from Britain, 
the US and Australia 
Diagnosis before 35 
years 
No 
Table 5. Genome-wide and major genetic studies performed in type 1 diabetes. Studies 2, 4 
and 6 performed metanalysis with the WTCCC data. Also, the last genome-wide carried out 
by Barrett et al (study 6) performed a meta-analysis of the three larger genome-wide studies 
(1, 4 and 6) performed in type 1 diabetes. 
The T1DGC (Type 1 Diabetes Genetics Consortium) is an initiative constituted in 2002 with 
the aim of providing resources to the research in type 1 diabetes. Since 2007, the consortium 
has published several studies on type 1 diabetes genetics (Erlich et al, 2008; Hakonarson et 
al, 2008; Howson et al, 2009; Qu et al, 2009) and, although the genome-wide study in which 
the T1DGC population was genotyped did not include an age-at-onset analysis, this group 
is lately including age-at-onset analyses in their publications and some of their studies have 
provided the first evidences of influence of genetics in age at onset of the post-genome wide 
era (Hakonarson et al, 2008). The selection criteria for adult patients are year at diagnosis 
under 35 years and uninterrupted insulin treatment for at least 6 months (Hakonarson et al, 
2007). However, despite the wider limit in age at onset in this population, the majority of the 
patients included are pediatric, as reflected in the mean age at onset (around ten years) 
found in the published studies (Hakonarson et al, 2008; Howson et al, 2009).    
4. Reported genetic associations of genes and age-at-diagnosis  
The influence of genetics in age at onset of type 1 diabetes has been analyzed in some 
studies. However, initiatives to replicate these first studies or to establish a protocol to 
analyze the genetics or early and late onset are lacking, and therefore there is disparity in 
the definition and selection of late-onset type 1 diabetes patients, and in the statistical 
methods employed to analyze the associations. In this section, we will review some selected 
studies on the influence of genetics in age at diagnosis of type 1 diabetes.    
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 Familial studies: analysis in monozygotic twins with one member affected with type 1 
diabetes have shown that the probability of developing the disease in the non-affected 
twin is considerably higher (38%) when the affected twin developed type 1 diabetes at 
an early age (under 24 years) than when the affected twin developed the disease after 25 
years of age (6% risk for the non-affected twin) (Redondo et al, 2001b). This observation 
might suggest that early-onset type 1 diabetes has a stronger genetic component 
(responsible of the higher concordance rate) than the same disease with a late onset.  
 HLA associations to age at onset: several studies (Redondo et al, 2001a; Leslie et al, 
2006; Klinker et al, 2010) have pointed out to the higher risk and earlier onset of type 1 
diabetes in patients that are heterozygote for the HLA class II risk haplotypes DRB1*03 
and DRB1*04-DQB1*03:02. On the other hand, the influence of HLA class I alleles in age 
at diagnosis has been thoroughly studied, and alleles B*39 and A*24 have been 
consistently associated to an earlier onset of the disease (Valdes et al, 2005; Nejentsev et 
al, 2007). The B*39 allele, for example, precipitates the age of diagnosis in four years 
(Valdes et al, 2005).    
 IL12B: the gene IL12B codes for the p40 subunit of the interleukin 12, also shared with 
interleukin 23. A 2004 study (Windsor et al, 2004) carried out in an Australian cohort 
including early and late onset patients found association of a polymorphism in position 
+1188 of the gene with late-onset of the disease (over 25 years). Neither associations on 
the IL12B gene with type 1 diabetes nor the described age-at-onset association have 
been replicated in recent studies.   
 CAPSL-IL7R: this region was first associated with type 1 diabetes in a study of non-
synonymous polymorphisms, finding a marker in the CAPSL gene that was highly 
associated with the disease (Smyth et al, 2006). Another polymorphism in the IL7R gene 
has been associated to type 1 diabetes and multiple sclerosis (Hafler et al, 2007; Todd et 
al, 2007). Our group undertook a replication study on both polymorphisms briefly after 
the discovery of the first signal (Santiago et al, 2008). We found association with type 1 
diabetes in both polymorphisms and also described that both markers were associated 
with an earlier onset, an effect more noticeable in the IL7R polymorphism.     
 Region 12q13 (ERBB3 gene): in a replication study of borderline significant signals from 
a previous genome-wide (Hakonarson et al, 2007), the T1DGC found evidence of the 
association of three 12q13 polymorphisms with age at diagnosis (Hakonarson et al, 
2008). The influence of this region on age at onset of type 1 diabetes has been 
subsequently analyzed in two independent studies (Awata et al, 2009; Wang et al, 2010) 
that, with different statistical methodology, did not replicate the effect seen in the first 
study. Finally, we have studied several signals in this region and found an age-at-
diagnosis effect stronger than the previously described, with homozygotes for the 
susceptibility allele having an age at onset five years earlier than carriers of protective 
alleles (Espino-Paisan et al, 2011b).  
 Region 2q32 (STAT4 gene): a study in 2008 described an association of polymorphisms 
in the STAT4 gene with type 1 diabetes patients with an onset earlier than 8 years (Lee 
et al, 2008). Among the polymorphisms studied was rs7574865, which we will include 
in our study on age at onset in section 5. This study was carried out in a pediatric 
Korean population, therefore population differences have to be taken in consideration, 
given that the genetics of Asian and Caucasian type 1 diabetes patients present some 
important differences (Ikegami et al, 2007).    
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 Insulin gene: the T1DGC group analyzed several classical type 1 diabetes genes 
(Howson et al, 2009) and found association of the susceptibility variant in the insulin 
gene to an onset of type 1 diabetes two years earlier than the protective allele. However, 
this effect was not replicated in one of the cohorts included in the study. We will 
analyze the same polymorphism in our study in section 5. 
 IL2RA: a Finnish study analyzed several classical type 1 diabetes genes in a group with 
late-onset of the disease (Klinker et al, 2010). They found associations of the insulin, 
PTPN22, IFIH1 and CTLA4 genes with late-onset patients, and replicated the age-at-
onset effect of the DRB1*03-DRB1*04-DQB1*03:02 heterozygote. They also found that 
IL2RA was associated with an earlier disease onset. However, the T1DGC studied the 
IL2RA gene and did not find any effect in age at onset, although they did not include 
the stronger association in the gene that the Finnish study did analyze (Howson et al, 
2009). Our group conducted a replication study in polymorphisms in the IL2RA gene 
and we found them associated to both early and late disease onset (Espino-Paisan et al, 
2011c).    
 PTPN22: a German group studied the C1858T polymorphism in the PTPN22 gene and 
found that the susceptibility polymorphism was associated to an earlier onset of the 
disease in a group of pediatric-onset patients (Kordonouri et al, 2010). Patients with the 
susceptibility polymorphism had an onset of the disease two years earlier than 
homozygotes for the protective allele. However, this observation was not replicated in 
the T1DGC study (Howson et al, 2009). We will study this polymorphism in our group 
of pediatric and adult patients in section 5. 
 PTPN2: our group studied the influence in age at disease onset of two polymorphisms 
in the PTPN2 gene that had been previously associated with type 1 diabetes (Todd et al, 
2007; WTCCC, 2007). We found that one of the studied polymorphisms was associated 
with an earlier disease onset, with carriers of the susceptibility allele having a disease 
onset almost three years earlier than homozygotes for the protective allele (Espino-
Paisan et al, 2011a). 
5. A practical study: Genetic analysis of a population with early and  
late-onset type 1 diabetes patients 
We have selected ten chromosome regions (five classical genes and five genome-wide 
discoveries) previously studied in type 1 diabetes to test their association with pediatric and 
late-onset patients. We will briefly review their role in the pathogenesis of the disease and 
compare our results with the previous reported associations.    
5.1 Population of study and methods 
A total of 444 type 1 diabetes patients (47% female) were included in this study. All patients 
were recruited from the Madrid area (Spain), all where Caucasoid and diagnosed according to 
the criteria of the American Diabetes Association (ADA, 2010). Age at diagnosis was available 
for 415 patients and ranged from 1 to 65 years. Mean age at onset of the population was 
18.611.1 years and median age at onset was 16 years. All patients were insulin-dependent since 
diagnosis and had been on uninterrupted insulin treatment for at least 6 months. Adult patients 
diagnosed over 35 years were included on the basis of positivity to autoantibodies, lean body 
type and insulin-dependency status. Also, a maximum of 888 ethnically matched controls 
(53.7% female) with no history of type 1 diabetes in first degree relatives were recruited.  
www.intechopen.com
 Type 1 Diabetes Complications 
 
40
Genes in the HLA complex were genotyped by two SSOP (Sequence Specific 
Oligonucleotide Probe) procedures: dot-blot hybridization and Luminex technology. The 
remaining genes were studied through genotyping of single nucleotide polymorphisms by 
TaqMan Assays in a 7900HT fast real-time PCR system (Applied Biosystems Foster City, 
CA, USA). The call rate for each SNP was 95%. A summary of these studied polymorphisms 
can be consulted in table 6. 
 
Chromosome Candidate gene SNP Assay reference Control MAF 
1p13 PTPN22 rs2476601 By design T (0.06) 
2q24 IFIH1 rs1990760 C___2780299_30 G (0.46) 
2q32.3 STAT4 rs7574865 C__29882391_10 T (0.21) 
2q33.2 CTLA-4 
rs231775 C___2415786_20 T (0.29) 
rs3087243 C___3296043_10 G (0.48) 
6q23.3 TNFAIP3 rs10499194 C___1575581_10 T (0.32) 
9q33.2 TRAF1 rs2269059 C__15875924_10 A (0.07) 
11p15.5 INS rs689 C___1223317_10 A (0.28) 
12p13.31 CLEC2D rs11052552 C__32169467_10 G (0.49) 
16p13.13 CLEC16A rs2903692 C__15941578_10 A (0.42) 
Table 6. Summary of the genotyped SNPs in each gene. MAF: minor allele frequency. 
No statistically significant deviations from Hardy-Weinberg equilibrium were found in the 
control subset for each polymorphism. A case-control analysis was performed to asses 
association of the selected variants with type 1 diabetes. Differences were calculated through 
Chi-square and Fisher’s exact tests when necessary. Analysis of age at onset was performed 
through a stratified and a continuous approach. For the stratified analysis, cases were 
classified in early-onset (age at diagnosis under 17 years) or late-onset (age at diagnosis over 
16 years) and compared with Chi-square test or Fisher’s exact test. Associations were 
estimated by the odds ratio (OR) with 95% confidence interval. All Chi-square and Fisher’s 
exact test comparisons were calculated with Epi Info v.5 (CDC, Atlanta, USA). For the 
continuous analysis approach, ages at onset associated to each allele were compared with 
the non-parametric U Mann-Whitney test implemented in SPSS v.15.0 (Chicago, Illinois, 
USA).  
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5.2 Selected genes and results 
5.2.1 Classical type 1 diabetes associations 
Class II HLA alleles (chromosome 6p21): class II HLA binds extra-cellular antigens 
processed by antigen presenting cells and presents them to CD4+ helper T cells. The 
proposed mechanism in the pathogenesis of type 1 diabetes takes place at the negative 
selection process during lymphocyte thymic maturation (Redondo et al, 2001a; Ounissi-
Benkalha and Polychronakos, 2008). Negative selection occurs when a T cell with an 
autoreactive T cell receptor (TCR) binds a HLA molecule loaded with an autoantigen. This 
union sends a strong activation signal through the TCR that is deleterious to the 
autoreactive T cell. Theoretically, susceptibility HLA alleles bind pancreatic antigens less 
efficiently, lowering the activation signal to non-deleterious levels and allowing the 
autoreactive T cell to escape from thymic selection.  
The HLA associations detected in our group in the case-control analysis and the study on 
age at onset can be consulted in table 7. Due to the high number of alleles and haplotypic 
combinations in this region, and the low frequency of some of them, a stratified analysis 
would imply a marked loss of statistical power, so we choose to perform only the 
continuous analysis. We did not find evidence of an influence in age at diagnosis in any of 
the haplotypic combinations included, which means that our adult-onset patients have the 
same HLA contribution to type 1 diabetes than our pediatric patients. Of notice, there are 
two haplotypes with a marked difference in the mean age at diagnosis: the DRB1*04-
DQB1*03:02 homozygote (carriers have an onset three years earlier) and carriers of the 
protective haplotype DRB1*15:01-DQB1*06:02 (carriers have an onset ten years later than 
non carriers). None of these comparisons are statistically significant, but it could be a 
problem of low statistical power since both genotypes are quite infrequent. A larger sample 
would be needed to elucidate the possible associations.  
Many studies describe the DRB1*03-DRB1*04 heterozygote as associated with earlier age at 
diagnosis of type 1 diabetes, and also as the haplotypic combination that confers a higher 
risk to the disease. In our population we do not see an age effect (p=0.9). Moreover, the 
DRB1*03-DRB1*04 heterozygote does not confer the higher risk, but the DRB1*04 
homozygote, the DRB1*03 or DRB1*04 carrier, and the DRB1*03 homozygote. 
Insulin gene (chromosome 11p15): the insulin gene is also proposed to participate in the 
generation of autoreactive T cells in the thymus. The polymorphism associated with type 1 
diabetes is a VNTR (variable number of tandem repeats) that locates upstream of the INS 
gene and modifies its expression in the thymus (Pugliese et al, 1997; Vafiadis et al, 1997). 
Alleles in this VNTR range from 26 to 210 repetitions of a consensus sequence and are 
usually classified in three groups: short class I alleles (26 to 64 repetitions), intermediate 
class II alleles (64 to 139 repetitions, infrequent in Caucasian and Asian populations) and 
large class III alleles (140 to 210 repetitions). Large alleles are associated with protection 
from type 1 diabetes and are related to a higher expression of insulin in the thymus 
(Vafiadis et al, 1997). This is thought to favor the negative selection of insulin-reactive T 
cells, a theory that would be consistent with the lower levels of insulin antibodies detected 
in patients that carry the large class III alleles (Hermann et al, 2005). We have selected a 
polymorphism (rs689) in linkage disequilibrium with the two main classes of alleles that is 
usually employed in genetic studies (Hermann et al, 2005; Todd et al, 2007; Smyth et al, 
2008) as a proxy to the VNTR genotyping.  
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Genotype 
Case-control analysis 
 
Genotype frequency p OR 
T1D Controls 
DR4-DQ8 homozygote 0.052 0.002 6.0x10-8 33.59 (5.40-1386) 
DR3-DQ2 carrier 
or 
DR4-DQ8 carrier 
0.894 0.384 2.1x10-61 13.24 (9.27-18.96) 
DR3-DQ2 carrier 0.143 0.015 3.1x10-16 11.19 (5.31-24.41) 
DR3-DQ2 
DR4-DQ8 
0.249 0.031 1.6x10-26 10.36 (6.11-17.75) 
DR4-DQ8 – X (not DR3) 0.256 0.123 3.7x10-8 2.43 (1.74-3.39) 
DR3-DQ2 – X (not DR4) 0.369 0.221 2.0x10-7 2.03 (1.53-2.69) 
DR2-DQ6 – X 0.011 0.186 4.5x10-19 0.05 (0.02-0.12) 
Table 7. Case-control analysis of selected HLA haplotypes. Comparisons were calculated 
with Chi-square and Fisher’s exact test when necessary. HLA haplotypes have been 
abbreviated: DR4-DQ8 (DRB1*04-DQA1*03:01-DQB1*03:02), DR3-DQ2 (DRB1*03-
DQA1*05:01-DQB1*02:01), DR2-DQ6 (DRB1*15:01-DQA1*01:02-DQB1*06:02). T1D: type 1 
diabetes. 
 
Genotype 
Continuous analysis 
Mean age at onset 
P 
Carrier Non carrier 
DR4-DQ8 homozygote 15.9 (11.5) 18.6 (11.1) 0.2 
DR3-DQ2 carrier 
Or 
DR4-DQ8 carrier 
18.3 (11.1) 19.4 (10.2) 0.4 
DR3-DQ2 carrier 17.5 (11.2) 18.6 (11.0) 0.2 
DR3-DQ2 
DR4-DQ8 
18.0 (10.7) 18.6 (11.2) 0.9 
DR4-DQ8 – X (not DR3) 18.0 (10.5) 18.9 (11.5) 0.7 
DR3-DQ2 – X (not DR4) 18.8 (11.9) 18.4 (11.5) 0.9 
DR2-DQ6 – X 28.0 (13.7) 18.5 (11.0) 0.2 
Table 7 (continuation). Analysis of age at onset in selected HLA haplotypes. Comparisons 
were calculated with the U Mann-Whitney test. HLA haplotypes: DR4-DQ8 (DRB1*04-
DQA1*03:01-DQB1*03:02), DR3-DQ2 (DRB1*03-DQA1*05:01-DQB1*02:01), DR2-DQ6 
(DRB1*15:01-DQA1*01:02-DQB1*06:02). T1D: type 1 diabetes.  
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In our study, we replicate the association previously described in the INS gene and we do not 
find effects on age at onset in the stratified and continuous analysis. Results are provided in 
table 8.  
 
Gene 
CASE-CONTROL AND AGE-STRATIFIED 
ANALYSES 
CONTINUOUS 
ANALYSIS 
MAF p OR 
Mean age at 
onset 
P 
Major 
allele 
Minor 
allele 
INS        
T1D-control 0.175 0.282 8.3x10-9 
0.54 
(0.43-0.67) 
19.3 
(11.8) 
18.0 
(10.7) 
0.4 
Pediatric-adult T1D 0.162 0.177 0.6     
CTLA4 rs231775        
T1D-control 0.328 0.299 0.1 
1.14 
(0.96-1.37) 
18.4 
(10.9) 
18.9 
(11.4) 
0.6 
Pediatric-adult T1D 0.323 0.339 0.6     
CTLA4 rs3087243        
T1D-control 0.477 0.518 0.05 
0.85 
(0.72-1.00) 
18.9 
(11.0) 
17.8 
(10.8) 
0.2 
Pediatric-adult T1D 0.493 0.451 0.2     
PTPN22        
T1D-control 0.115 0.064 7x10-6 
1.91 
(1.42-2.56) 
18.4 
(11.2) 
19.0 
(10.6) 
0.4 
Pediatric-adult T1D 0.113 0.127 0.5     
IFIH1        
T1D-control 0.373 0.409 0.1 
0.86 
(0.70-1.06) 
17.2 
(10.3) 
17.2 
(10.6) 
0.9 
Pediatric-adult T1D 0.373 0.394 0.6     
Table 8. Analysis of classical gene associations in type 1 diabetes. Minor allele frequency 
(MAF) is provided in case-control and age-stratified analyses, and comparisons were 
calculated with Chi-square and Fisher’s exact test when necessary. In the continuous 
analysis, mean ages at onset associated to each allele and the p value from the U Mann-
Whitney test are presented. INS: insulin gene. T1D: type 1 diabetes.  
CTLA4 (chromosome 2q33): this gene encodes a negative regulator of lymphocytic 
activation. Its expression is induced in activated lymphocytes, but it is also constitutively 
expressed in regulatory T cells, a lymphocyte subpopulation specialized in the suppression 
of autoimmunity. Also, a soluble form of CTLA4 is secreted in the serum, and it is believed 
that this form contributes to the downregulation of activation in the immune system (Ueda 
et al, 2003). Several polymorphisms have been identified and associated with type 1 diabetes 
(Ueda et al, 2003; Qu et al, 2009). We have selected two functional polymorphisms: one 
aminoacidic change related to lower membrane expression of the protein (rs231775) and a 
polymorphism in the 3’ end that is related to higher expression of soluble CTLA4 
(rs3087243), which also is one of the strongest associations with type 1 diabetes in the gene 
(Ueda et al, 2003; Qu et al, 2009).  
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We replicate the association described in CTLA4 rs3087243.  Differences in CTLA4 rs231775 
do not reach statistical signification, but this could be due to low statistical power to detect 
the previously described association (Ueda et al, 2003). We do not find effects of any of the 
polymorphisms on age at onset. Results can be consulted in table 8.
PTPN22 (chromosome 1p13): this gene encodes a lymphoid-specific phosphatase called 
LYP, which is an important downregulator of T cell activation through the TCR. We selected 
the classical non-synonymous polymorphism C1858T that causes a substitution from 
arginine to tryptophan in the aminoacid 620 of the encoded protein (Bottini et al, 2004). The 
mutant form shows a higher phosphatase activity, and therefore it suppresses T cell 
activation more efficiently. Its role in type 1 diabetes is believed to be at the thymic selection 
process, where the mutant PTPN22 would lower the activation signal sent to the 
autoreactive T cell through its TCR, thus contributing to its survival (Bottini et al, 2006). It 
also has been proposed that the increased suppression of activation associated to the mutant 
form could affect negatively the activation of regulatory T cells (Bottini et al, 2006). 
We replicate the association previously described in the PTPN22 gene and we do not find 
effects on age at onset in the stratified and continuous analysis. Results can be consulted in 
table 8.  
IFIH1/MDA5 (chromosome 2q24): certain viral infections such as that caused by 
Enterovirus are more prevalent in type 1 diabetes patients than in the healthy population, 
and it has been proposed that they could participate in the development or acceleration of 
the immune response against the  cell (Hober & Sauter 2010). The helicase IFIH1 recognizes 
viral double stranded RNA (dsRNA) and it is expressed in the cytoplasm of several cells, 
including  cells. In the presence of a viral infection, IFIH1 binds the dsRNA and induces the 
synthesis of pro-inflammatory cytokines. Functional experiments show that protection from 
type 1 diabetes is achieved through a lower performance of the sentinel role of IFIH1 that 
would end up in lower activation of the immune system in response to the viral infection 
(Colli et al, 2010).   
We detect a lower frequency of the minor allele of IFIH1 in type 1 diabetes patients respect 
to controls; however this difference is not statistically significant, probably due to low 
statistical power of our study. We do not find effects on age at diagnosis of type 1 diabetes 
in the stratified and continuous analysis. Results are provided in table 8. 
5.2.2 Genome-wide associations 
Region 2q32 (STAT4): the gene STAT4 is an interesting candidate for type 1 diabetes. 
Member of a family of transcription factors, STAT4 activates the transcription of several 
genes including IFN- in response to interleukin-12 signaling. The pathway IL12-STAT4-
IFN polarizes the immune response to a Th1 type, the kind of response that is thought to 
be responsible of the type 1 diabetes autoimmune reaction (Raz et al, 2005). We have 
selected a polymorphism that was first discovered associated with rheumatoid arthritis 
(Remmers et al, 2007). Our group studied this polymorphism in several autoimmune 
diseases and described its association with type 1 diabetes (Martinez et al, 2008), as it can 
be seen in table 9. Influence of this polymorphism in age at onset has been previously 
studied in a pediatric-onset Korean population, as we described in section 4. We 
performed a stratified and continuous analysis of age at onset and we did not find 
evidences of the influence of this polymorphism in age at onset of the disease. Results can 
be consulted in table 9. 
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Gene 
CASE-CONTROL AND AGE-STRATIFIED 
ANALYSES 
CONTINUOUS 
ANALYSIS 
MAF p OR 
Mean age at 
onset 
P 
Major 
allele 
Minor 
allele 
2q32 (STAT4)        
T1D-control 0.240 0.192 0.01 
1.33 
(1.05-1.68) 
17.6 
(10.6) 
16.7 
(9.4) 
0.6 
Pediatric-adult T1D 0.237 0.250 0.7 --    
6q23 (TNFAIP3)        
T1D-control 0.282 0.321 0.05 
0.83 
(0.69-1.01) 
18.7 
(11.1) 
17.8 
(10.6) 
0.3 
Pediatric-adult T1D 0.297 0.271 0.4 --    
9q33 (TRAF1)        
T1D-control 0.085 0.071 0.2 -- 
18.4 
(11.1) 
21.2 
(10.5) 
0.02 
Pediatric-adult T1D 0.063 0.104 0.04 --    
12p13 (CLEC2D)        
T1D-control 0.462 0.504 0.06 
0.85 
(0.71-1.01) 
17.6 
(10.7) 
18.5 
(11.0) 
0.4 
Pediatric-adult T1D 0.471 0.460 0.8 --    
16p13 (CLEC16A)        
T1D-control 0.368 0.416 0.05 
0.82 
(0.66-1.01) 
16.9 
(9.7) 
18.0 
(11.5) 
0.5 
Pediatric-adult T1D 0.359 0.394 0.4 --    
Table 9. Analysis of selected gene associations from genome-wide studies in type 1 diabetes. 
Minor allele frequency (MAF) is provided in case-control and pediatric vs adult onset 
analyses, and comparisons are calculated with Chi-square and Fisher’s exact test when 
necessary. In the continuous analysis, mean ages at onset associated to each allele and the p 
value from the U Mann-Whitney test are presented. T1D: type 1 diabetes.  
Region 6q23 (TNFAIP3): two polymorphisms located in an intergenic space adjacent to the 
TNFAIP3 gene have been associated to several autoimmune diseases, among them type 1 
diabetes (Fung et al, 2009). We have selected the polymorphism that shows a stronger 
association with the disease. The gene TNFAIP3 is expressed in  cells and serves as an anti-
inflammatory mechanism by its downregulation of the NF-B activation (Liuwantara et al, 
2006); therefore, it poses an interesting candidate gene in the pathogenesis of type 1 
diabetes. To our knowledge, this is the first time that this region is studied in relation to its 
influence in age at onset. 
In our study, we replicate the association previously seen in type 1 diabetes and we do not 
find differences in age at onset either in the stratified or continuous analyses. Results are 
provided in table 9. 
Region 9q33 (TRAF1): this region was first associated to rheumatoid arthritis (Kurreeman 
et al, 2007). Our group took part in a collaborative study that analyzed this region in 
several autoimmune diseases and found association with type 1 diabetes, among others 
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(Kurreeman et al, 2010). As an extension of the cited study, we selected and studied new 
polymorphisms in the TRAF1 gene and analyzed their influence in age at onset of the 
disease. We present in table 9 the results obtained in one polymorphism that has not been 
previously studied in type 1 diabetes. Like TNFAIP3, the gene TRAF1 is expressed in 
cells and protects them against cytokine-mediated apoptosis in an inflammatory 
environment (Sarkar et al, 2009).  
The polymorphism in TRAF1 shows interesting data (table 9). We do not see statistical 
differences in the case-control analysis, but the age-stratified analysis shows an elevation 
of the minor allele frequency only in the adult-onset patients, that is statistically 
significant when compared to pediatric patients (p=0.04) and to controls (OR=1.52 [1.00-
2.31]; p=0.04). On the other hand, the pediatric patients are similar to controls (p=0.6). The 
continuous analysis confirms the difference observed in the stratified analysis, showing 
an age at onset associated to the minor allele (mean 21.2) that is almost three years higher 
than the age at onset associated to the major allele (mean 18.4). Therefore, there seems to 
exist an association in this gene that is exclusive of our adult-onset type 1 diabetes 
patients.  
Region 12p13 (CLEC2D): first associated with type 1 diabetes in the WTCCC study 
(WTCCC, 2007), it includes several genes. Polymorphisms associated with the disease 
(WTCCC, 2007; Barrett et al, 2009) have been identified in the surroundings of two genes 
with immunological function: CLEC2D and CD69. We will focus on the polymorphism near 
CLEC2D (coding the NK receptor LLT1), which was the strongest signal reported by the 
WTCCC (WTCCC, 2007) in this region. To date, the influence of region 12p13 on age at 
onset has not been studied. 
In our study, we detect a trend towards association with type 1 diabetes of the studied 
polymorphism. We do not find differences in age at onset in the stratified and continuous 
analyses. Results are provided in table 9. 
Region 16p13 (CLEC16A): this region was one of the most strongly associated with type 1 
diabetes in the WTCCC (WTCCC, 2007) and was also discovered independently in a parallel 
study (Hakonarson et al, 2007). It covers a gene of unknown function termed CLEC16A, 
which is expressed in antigen presenting cells and NK cells, but little else is known about 
this gene or its possible role in the pathogenesis of the disease. Our group replicated the 
association detected in the WTCCC study (Martinez et al, 2010). Here we will analyze its 
influence in age at onset. 
We replicate the association previously seen in type 1 diabetes. We do not find differences in 
age at onset in the stratified and continuous analyses. Results are provided in table 9. 
5.3 Discussion 
In this study we analyzed ten genetic regions, five of them classical type 1 diabetes genes 
and another five extracted from recent genome-wide studies. The analysis of age at onset 
(either age-stratified or considering age as a continuum) did not provide statistical 
differences in nine of the ten regions studied, therefore we propose that our adult-onset 
patients have the same genetic background in the studied genes that our pediatric-onset 
patients. Hence there is no reason to exclude these late-onset patients from genetic studies 
on type 1 diabetes. The results we observe in the classical type 1 diabetes susceptibility 
genes (table 8) are concordant with a recent Finnish study (Klinker et al, 2010) that analyzes 
these genes in late-onset patients and finds the same associations previously described in 
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pediatric-onset type 1 diabetes. Also, a recent study from the T1DGC (Howson et al, 2009) 
that replicated 19 genes, including PTPN22, IFIH1 and CTLA4, studied age at onset in each 
one and did not find statistical differences, supporting the idea that the classical genetic 
associations to type 1 diabetes are shared between the early and late onset patients.  
Interestingly, in our population we do not find differences in the HLA associations with 
early and late onset. It has been described before that the DRB1*03-DRB1*04 heterozygote 
is the combination that confers a higher risk and it is associated with an earlier age at 
onset of type 1 diabetes (Redondo et al, 2001a; Leslie et al, 2006; Klinker et al, 2010). 
However, in our population the heterozygote is the fourth combination in risk conferred 
to the disease after the DRB1*04-DQB1*03:02 homozygote, the DRB1*03 or DRB1*04-
DQB1*03:02 carrier and the DRB1*03 homozygote, and we do not see an effect on age at 
diagnosis of the heterozygote. This could be due to populational differences, quite 
important in the HLA complex. It is well known that not all the DRB1*03 haplotypes 
confer the same susceptibility to the disease. An extended conserved haplotype marked 
by B*18-DRB1*03-DQB1*02:01 is described to confer higher susceptibility among the 
DRB1*03-carrying haplotypes (Johansson et al, 2003; Urcelay et al, 2005). This haplotype is 
more frequent in the Mediterranean area and its frequency descends in Northern Europe. 
Therefore, it could be possible that the higher frequency of this high risk haplotype 
enhances the risk conferred by being a DRB1*03 homozygote in a Mediterranean 
population such as the Spanish.   
A recent study with the T1DGC family cohort (Howson et al, 2009) found a mild effect of the 
insulin gene in age at diagnosis of the disease, with the susceptibility allele conferring an 
onset two years earlier than the protective allele. We do not see an effect on age at diagnosis 
(continuous analysis, p=0.4). Moreover, in the aforementioned Finnish report, the authors 
also studied the INS gene and found association in late onset patients (Klinker et al, 2010). It 
is possible that our study lacks statistical power to detect a difference of two years in the age 
at diagnosis. However, the authors of the T1DGC study tried to replicate their findings in a 
case series of 900 patients and did not find the effect they saw in the family cohort, opening 
the door to the possibility that the described effect is a false positive.   
Finally, we find that TRAF1 is only associated to late-onset type 1 diabetes. Although our 
study is limited by low statistical power and would require replication in an independent 
late onset type 1 diabetes cohort, this is an interesting finding that would justify the study of 
the late-onset patients as a distinct set among the type 1 diabetes patients.   
From the study of these ten genetic regions in our group composed of early and late onset 
patients, we propose that there are no major genetic differences between patients with an 
early and a late onset of type 1 diabetes.  
6. Conclusions 
Although the knowledge on the genetics of type 1 diabetes has experienced a great 
development in the last years, it has not provided many hints on the basis of the genetic 
components that could modify the age at onset of the disease. Several studies have 
approached the subject, but few of the reported associations have been properly 
replicated in independent populations. Also, the heterogeneity in the methodology of the 
published studies should be discussed: some studies select only paediatric patients. If the 
influence of a genetic region reaches a peak in the paediatric age and then decreases with 
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time, a study with paediatric and adult patients would better estimate the difference 
than a study with only paediatric patients in which the difference may be seen, but also 
may be smaller than it really is. The majority of the published studies analyze the age at 
diagnosis of type 1 diabetes as a continuous variable, but some studies adopt a stratified 
analysis that implies the fragmentation of the patients in two or more groups and the 
individual analysis of each subgroup. This strategy defines artificial groups with limits 
that do not have a biological justification, and makes it more likely to produce false 
results in underpowered studies. We recommend the age-stratified analysis as a 
screening method or as a confirmation analysis, but we consider the analysis of age as a 
continuous variable a more accurate method to detect differences, given that it only takes 
into consideration the genotype studied and the ages at onset of all the patients carrying 
this genotype. Therefore, we propose that age at diagnosis of type 1 diabetes should be 
studied in groups that include paediatric and adult onset patients, and that the statistical 
analysis should include at least one method that considers age at diagnosis as a 
continuum.  
Despite the improvements that can be incorporated to age-at-onset analysis, what is known 
to date about the influence of the genetics on the early and late onset of type 1 diabetes 
allows us to formulate a tentative answer to the question that gives title to this chapter: are 
early and late onset type 1 diabetes the same or two distinct genetic entities? Our data, 
presented in section 5, and the previous studies reviewed in section 4 suggest that there are 
no major differences in the genetic component of paediatric and adult patients. Both share 
the risk conferred by the main type 1 diabetes risk modifiers such as the HLA, the insulin 
gene or PTPN22. However, two points have to be taken into consideration: first, minor 
differences can be found between the adult and the paediatric patient, such as the elevated 
prevalence of the higher risk HLA alleles in subjects with early onset. Second, the genetics of 
adult-onset type 1 diabetes patients has frequently been studied only in relation to genes 
that already showed association in paediatric patients. This approach precludes the 
possibility of discovering genes that could be associated exclusively to late-onset type 1 
diabetes. The study of these two points is of great interest given that it could point to 
metabolic routes that take part in the acceleration of the disease and, therefore, genes in 
these routes would be excellent candidates for therapeutic strategies focused on the delay of 
the autoimmune  cell destruction. 
In conclusion, we propose that type 1 diabetes, whether in its early or late-onset, is an 
autoimmune disease defined by a number of primary risk genes and a constellation of 
minor genetic modifiers that, together with environmental factors, define the pace of the 
autoimmune reaction that will determine the age at onset. 
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